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| INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) has gradually become a wide spread disease affecting 40-50% of the general population 1 with serious hepatic outcomes including progression of non-alcoholic steatohepatitis (NASH) to advanced fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Liver biopsy still serves as reference standard in the diagnosis of NASH but is afflicted with major drawbacks such as feasibility, sampling error, intra-and interobserver variability and potential complications 2 also lacking a functional in-vivo assessment.
Therefore, non-invasive tools to monitor severity and progression of NAFLD are urgently needed.
Proton ( 1 H)-and phosphorus ( 31 P)-MR spectroscopy (MRS) might
allow a non-invasive and real-time detection of hepatic fat, cell membrane and energy metabolism. 3, 4 3 Tesla (T) 1 H-MRS is an effective tool to quantify liver steatosis 5 and assess hepatic lipid composition. 6 Data from 31 P-and carbon-13 ( 13 C)-MRS on hepatic energy 7 and hepatic oxidative metabolism 8 have already shown the utility evaluating the important role of the liver in the general regulation of glucose and lipid metabolism. However, most of the previously published studies on 31 P-MRS in NAFLD were limited to magnetic field strengths of 3 T or lower. 9, 10 Higher magnetic field strengths result in an increased signal-to-noise ratio and higher spectral resolution, which is of particular importance for 31 P-MRS. 11 We therefore explored the potential of high field 3 T 1 H and ultra-high field 7 T 31 P-MRS as a non-invasive tool in NAFLD patients to obtain (i) novel mechanistic insights of lipid, cell membrane and energy homoeostasis in NAFLD and, (ii) novel imaging biomarkers of disease severity and progression including endoplasmic reticulum (ER) stress. In addition, we determined the rs738409 [G] polymorphism of patatinlike phospholipase domain-containing protein 3 (PNPLA3) and the transmembrane 6 superfamily 2 (TM6SF2) rs58542926 variants associated with liver steatosis, progression of liver disease and its complications, 12-14 which has not been explored in the context of MRS so far.
| PATIENTS AND METHODS

| Study design
This was a prospective, non-randomized feasibility study of high field 1 H-and ultra-high field 31 P-MRS as a novel and non-invasive tool for the assessment of NAFLD. It was approved by the ethics commit-
tees of the Medical University Vienna and the Vienna General Hospital
(2011/129). All patients provided written informed consent.
| Subjects
Subjects scheduled for routine liver biopsy with suspected NAFLD were recruited from the NAFLD outpatient clinic of the Medical University Vienna (Figure 1 ). Histological assessment was performed by two board certified pathologists (JS, FW) unaware of the MRS data serving as reference standard for the diagnosis of NAFL, NASH, severity of inflammation and fibrosis (see below). Moreover, we collected comprehensive medical history and clinical data including physical examination, liver biochemistry, glycaemic parameters and lipid profiles (Table 1) .
Results: 
Key points
• Saturation transfer including dynamic ATP flux is significant lower in NASH than NAFL.
• Higher ratios of PCr/TP and lower ratios of γATP/TP support data on apparent mitochondrial defects in NASH.
• Ultra-high field MRS leads to shorter acquisition times and may therefore improve clinical applicability.
• Poly-to monounsaturated fatty acid indices were significantly higher in non-obese (BMI<30) than obese (BMI>30) NAFLD patients.
| Inclusion and exclusion criteria
Patients had to be between 18 and 70 years old and scheduled for liver biopsy with suspected NAFLD. Exclusion criteria were as followed: (i) established chronic liver diseases other than NAFLD (ie, viral hepatitis, autoimmune liver disease, hereditary hemochromatosis, alpha-1-antitrypsin deficiency, Wilson′s disease, alcoholic liver disease and cholestatic liver diseases). Patients were excluded in case of: (ii) daily alcohol consumption >30 g in males and >20 g in females, (iii) age <18 years, (iv) acute diseases within the last 2 weeks before the investigation, (v) severe or untreated heart, kidney, lung and blood disease (eg, heart failure NYHA III or IV, CKD stage >2, COPD Gold >2, any haematopoietic or lymphoid malignancy), (vi) current unstable thyroid disease, (vii) pregnancy, (viii) contraindications to MRS or liver biopsy.
| Genetic testing
Single nucleotide polymorphisms rs738409 (PNPLA3) and rs58542926 (TM6SF2) were analyzed using the StepOnePlus Real Time PCR Systems (Applied Biosystems; Foster City, CA, USA) with a TaqMan SNP Genotyping Assay developed together with Applied Biosystems using published sequences from the NCBI Entrez SNP Database.
| MR-spectroscopy
MR spectroscopy was performed in fasting conditions, early in the morning within a 2-hour time frame prior to liver biopsy.
| 1 H-MRS
Hepatic steatosis and hepatic lipid composition were measured using single voxel PRESS sequence (TE=30 ms, TR=2000 ms, VOI: with the whole body RF coil for excitation and the combination of body-matrix and spine coil, supplied by system manufacturer, for signal acquisition. Representative spectra and typical VOI position are depicted in Figure 2 (panel A-C). Spectra were analyzed with AMARES within jMRUI 15 and fat total signal area (FTSA-equal to hepatic steatosis) was assessed as the ratio of lipid signals (0.9-2.8 ppm) to the F I G U R E 1 Patient selection patients were invited to participate in this study if liver biopsy was planned in suspected non-alcoholic fatty liver disease (NAFLD) patients and magnetic resonance eligibility was confirmed. After obtaining consent patients were further selected when liver biopsy showed NAFLD non-alcoholic fatty liver or nonalcoholic steatohepatitis as single diagnosis Lipid composition was assessed as lipid saturation (SI), unsaturation (UI), polyunsaturation (PUI) and monounsaturation (MUI) indices calculated as published before. : steatosis involving <5% of cells (S0, no steatosis), 5%-33% (S1, mild), >33%-66% (S2, moderate) and >66% (S3, severe) of hepatocytes; ballooning was graded as none (0), few balloon cells (1) and many cells/prominent ballooning (2); lobular inflammation was graded as no foci (0, none), <2 foci (1, mild), 2-4 foci (2, moderate) and >4 foci per 200× field (3, marked); fibrosis was staged as none (F0), perisinusoidal or periportal (F1), perisinusoidal and portal/periportal (F2), bridging fibrosis (F3) and cirrhosis (F4). The diagnosis of non-alcoholic fatty liver (NAFL) was made if steatosis was ≥5% and either ballooning or lobular inflammation or both were absent. The diagnosis of NASH was made given that: (i) steatosis was ≥5%, (ii) ballooning and lobular inflammation were present. 22 Clinical differentiation was made for fibrosis stages 0-2 as no/mild fibrosis and for stages 3 and 4 as advanced fibrosis.
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| Statistical analysis
Statistical analysis was performed with commercially available soft- 
| RESULTS
| Patients' characteristics
Thirty patients with NAFLD undergoing liver biopsy between 2010 to 2013 were included in this study (Figure 1) , eight of them with NAFL and 22 with NASH (clinical characteristics see Table 1 ). No difference between sex and age was observed between both groups. NASH patients had a significantly higher BMI and WHR. Non-obese (BMI<30) and obese (BMI>30) NAFLD patients were equally distributed with no significant difference between NAFL and NASH. In this cohort, only patients with NASH had diabetes. Concomitant anti-diabetic therapy included metformin in six patients and diabetic diet only in two patients.
Eight patients had statin therapy without statistical differences between the two groups. In addition, there was no significant difference in serum cholesterol or HOMA index. The contribution of the PNPLA3 rs738409 polymorphism was only significantly different between NASH and NAFL for genotype GG (148M/M) (P=.003), which was not significant for TM6SF2 variants. Histology data is shown in Table 2 . 
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| Phosphomonoesters and phosphodiesters
PE/(PME+PDE) (P=.04), PE/γ-ATP (P=.002) and PE/TP (P=.015) ratios as markers of cell membrane turnover were lower in patients with no/mild fibrosis (F0-2) than advanced fibrosis F3-4. This was also observed for PME/γ-ATP ratios (P=.013). Inversely, GPC/(PME+PDE) ratios (P=.05) as cell membrane breakdown products were higher in no-to-mild fibrosis compared to advanced fibrosis ( Figure 4 ). There was no correlation with lobular inflammation but slightly higher PME/ TP ratios in grade 2 ballooning than in grade 1 (grade 2>1; P=.015) without difference to grade 0 (grade 1>0; P=.28). NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis.
T A B L E 2
Patients diagnosed with non-alcoholic steatohepatitis NASH in histology needed at least one point for ballooning and lobular inflammation, respectively, with grade 1 or higher in hepatic steatosis. 
| DISCUSSION
To our best knowledge, this is the first prospective clinical trial evaluating overall hepatic (3 T) 1 H-and (7 T) Lipid saturation with higher prevalence of potentially more toxic unsaturated fatty acids may be a critical determinant of lipotoxicity. 25 We therefore used 1 H-MRS to assess lipid saturation profiles (ie, SI, UI, MUI, PUI) but observed no differences between NAFL and NASH, non-diabetics and diabetics or different stages of fibrosis.
Interestingly, hepatic PUI to MUI ratios were significantly higher in non-obese (BMI<30) than obese (BMI>30) NAFLD patients. Notably, our results are in line with hepatic lipidomic analysis of NAFLD showing no difference between NAFL and NASH. 26 In addition, hepatic PUI was increased in homozygous carriers of the PNPLA3 I148M variant (G/G), which may be considered as a specific subtype of NASH 27 but not in any TM6SF2 variant.
NAFLD/NASH is a condition possibly characterized by ER stress.
28
We tested the hypotheses that ultra-high field 31 P-MRS may uncover alterations in phospholipid metabolites such as PME and PDE previously prescribed as markers of hepatic endoplasmic stress. 29 However, we did not observe any differences in PMEs and PDEs possibly due to a higher differentiation of the PME and PDE signals at 7 T. Levels of PE were lower in no-to-mild than in advanced fibrosis, which was also reflected by PME/γ-ATP ratios. Inversely, GPC/(PME+PDE) ratios were higher in advanced fibrosis supporting former data. 30 Our results reflect alterations in cell membrane metabolism in advanced NASH as described in diffuse liver disease, 31 fibrosis and cirrhosis. 32 In this study, we uncovered decreased ratios of γ-ATP/TP in advanced fibrosis indicating a disturbed energy metabolism in advanced steatohepatitis. Decreasing concentrations of hepatic ATP were also shown in patients with type 2 diabetes 33 which could not be shown in our cohort. Nevertheless, multivariate analysis was performed adjusting for possible effects of diabetes, BMI and WHR on hepatic energy metabolism, not changing the original findings.
Previous studies uncovered hepatic mitochondrial structural defects and functional mitochondrial abnormalities in NASH.
17,34
This may indicate that changes in hepatic energy homoeostasis and increased oxidative stress in NASH could promote cell injury and inflammation. In this study, PCr/γ-ATP and PCr/TP ratios increase with advanced fibrosis supporting the concept of dysfunctional mitochondria in advanced NASH. 10, 35 To exclude contamination of hepatic 31 P-MRSI data by signals from skeletal muscle, we carefully analyzed our acquisition scheme and compared presented data post hoc with data from healthy volunteers partially published before.
18
The retrospective analysis of these identically acquired spectra experimental models. 37 Our results might be therefore explained by a compensatory up-regulation of CK expression in advanced NASH with more advanced fibrosis due to a dysfunctional hepatic microvasculature 38 and hypoxia. 39 NADPH additionally increased with higher grades of hepatocellular ballooning possibly reflecting higher oxidative activity during inflammation 40 formerly shown in NASH. 30 
F I G U R E 4
31 P-MRS: Phosphomonoesters and phosphodiesters uncover alterations in cell membrane metabolism in non-alcoholic fatty liver disease (NAFLD). Phosphomonoesters like phosphoethanolamine (PE) were significantly higher in advanced fibrosis than no-to-mild fibrosis: (A) PE/phosphomonoester (PME)+phosphodiester(PDE) (P=.04), (B) PE/γ-adenosine triphosphate (ATP) (P=.002) and (C) PME/γ-ATP (P=.013). (D) This was reversed for phosphodiesters like glycerophosphocholine (GPC)/(PME+PDE) (P=.05).
31
P-MRS shows alterations in cell membrane metabolism in advanced NAFLD with higher degree of fibrosis Finally, we used the saturation transfer technique to assess dynamic Pi-to-ATP exchange parameters in NAFL and NASH, which was already used to monitor changes in the Pi-to -ATP flux reflecting alterations in the mitochondrial metabolism in the human muscle 41 not
shown for liver tissue so far. The exchange rate constant k and the unidirectional forward exchange flux F ATP were significantly lower in patients with NASH than with NAFL even after correction for the effects of diabetes, BMI and steatosis emphasizing our pilot study results 19 in showing a disturbed energy metabolism in NASH. Both, increased F I G U R E 5 31 P-MRS: adenosine triphosphate (ATP), inorganic phosphate, phosphocreatine and nicotinamide adenine dinucleotide phosphate (NADPH) reflecting altered energy metabolism in nonalcoholic fatty liver disease (NAFLD). fatty acid β-oxidation and hepatic oxidative stress are common in NAFLD. 34 However, a loss of adaptive mechanisms in mitochondrial function and mitochondrial structural defects has only been associ- Figure S1 ) showing regenerating Pi-to-ATP exchange parameters when hepatic steatosis improved (n=2) while revealing further impairment of Pi-to-ATP exchange parameters in case (n=1) of increasing hepatic steatosis, which at this point is rather preliminary and speculative until more extensively investigated.
As limitations of our study we have to acknowledge that the sample volume of liver biopsies and the region of interest measured by MRS are different, which is due to technique limitations in liver biopsy. This study was planned as a pilot study to evaluate the feasibility of extended high and ultra-high field with more advanced disease due to the requirements for routine liver biopsy indication. Conversely, the subjects characterized by NAFL were clustered in a rather low range of the steatosis scale. However, a major strength of this study is the exact timeline with short intervals and constant fasting conditions at which MRS and liver biopsy were conducted.
In conclusion, 3 T 
